Рациональная фармакотерапия в кардиологии (Jan 2016)

SAFETY OF AMIODARONE USAGE IN PATIENTS WITH WOLFF-PARKINSON-WHITE SYNDROME AND ATRIAL FIBRILLATION

  • D. A. Kuzhel,
  • G. V. Matyushin,
  • E. A. Savchenko

DOI
https://doi.org/10.20996/1819-6446-2010-6-3-359-362
Journal volume & issue
Vol. 6, no. 3
pp. 359 – 362

Abstract

Read online

Amiodarone is one of the basic antiarrhytmic drugs for atrial fibrillation treatment. However application of amiodarone in patients with atrial fibrillation and Wolff-Parkinson-White syndrome can induce ventricular fibrillation. Amiodarone usage in these patients should be accompanied by readiness for performance of resuscitation. This is confirmed by clinical case presentation.

Keywords